Direkt zum Inhalt
Merck

Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer.

The Journal of biological chemistry (2015-01-28)
Fernanda I Staquicini, Ming D Qian, Ahmad Salameh, Andrey S Dobroff, Julianna K Edwards, Daniel F Cimino, Benjamin J Moeller, Patrick Kelly, Maria I Nunez, Ximing Tang, Diane D Liu, J Jack Lee, Waun Ki Hong, Fortunato Ferrara, Andrew R M Bradbury, Roy R Lobb, Martin J Edelman, Richard L Sidman, Ignacio I Wistuba, Wadih Arap, Renata Pasqualini
ZUSAMMENFASSUNG

Lung cancer is often refractory to radiotherapy, but molecular mechanisms of tumor resistance remain poorly defined. Here we show that the receptor tyrosine kinase EphA5 is specifically overexpressed in lung cancer and is involved in regulating cellular responses to genotoxic insult. In the absence of EphA5, lung cancer cells displayed a defective G1/S cell cycle checkpoint, were unable to resolve DNA damage, and became radiosensitive. Upon irradiation, EphA5 was transported into the nucleus where it interacted with activated ATM (ataxia-telangiectasia mutated) at sites of DNA repair. Finally, we demonstrate that a new monoclonal antibody against human EphA5 sensitized lung cancer cells and human lung cancer xenografts to radiotherapy and significantly prolonged survival, thus suggesting the likelihood of translational applications.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-Phospho-ATM(Ser1981)-Antikörper, Klon 10H11.E12, clone 10H11.E12, Upstate®, from mouse